glp-1 agonist drug interactions Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review Evaluating the indirect interaction between
Description
Not just normal
Based on the route of administration, the GLP-1 receptor agonist market is classified into parenteral and oral segments
A network meta-analysis of 22 RCTs covering 2,258 participants found GLP-1 receptor agonists reduced lean mass by a mean of 0.86 kg, with lean mass comprising roughly 25% of total weight lost across agents
Preclinical Evidence Animal studies demonstrate reproductive toxicity, including skeletal and visceral abnormalities, dose-dependent growth restriction, and embryonic death
